New State of the Art Facility Increases Agilent’s Capacity to Produce Nucleic Acid-Based Therapeutics
June 18 2019 - 8:00AM
Business Wire
New facility in Frederick, Colorado, to produce high-quality
molecules with the potential to treat cancer and other diseases
Agilent Technologies Inc. (NYSE: A) today announced the opening
of a production facility in Colorado that more than doubles its
capacity to develop and manufacture “oligos,” which are short DNA
and RNA molecules that customers use to produce nucleic acid-based
therapeutics.
Agilent expects the demand for therapeutic oligo manufacturing
to grow near 10% each year through 2025, to over $750 million by
2025. This facility will enable Agilent to meet this growing demand
and to continue being a partner of choice to pharmaceutical and
biotech companies. Shipments to customers from this new site are
expected by year-end.
The new state-of-the-art facility is in Frederick, about 30
miles north of Denver. It produces oligonucleotide (“oligo”) active
pharmaceutical ingredients, which hold the potential to treat
cancer, rare and infectious diseases, cardiovascular indications,
and other disorders.
“Our customers are developing innovative therapies that can lead
to truly life-changing outcomes for patients,” said Brian
Carothers, vice president of Agilent’s Nucleic Acid Solutions
Division. “As a leading oligo manufacturer for over 20 years,
Agilent is uniquely qualified to support this critical and growing
industry. Our Frederick facility ensures we will keep up with
demand while continuing to deliver a premium customer service.”
“We’re committed to Frederick and the state of Colorado,” added
Carothers. “Agilent has already brought 100 high-paying jobs to
Frederick. Depending on customer demand, the site can further
expand its manufacturing capacity in the coming years.”
The $185 million facility in Frederick covers 135,000 square
feet. It also expands Agilent’s presence in Colorado, where the
company has had an oligo manufacturing site in nearby Boulder since
2006. Both sites are current Good Manufacturing Practices (cGMP)
facilities, as designated by the U.S. Food and Drug
Administration.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. With more than
50 years of insight and innovation, Agilent instruments, software,
services, solutions, and people provide trusted answers to
customers' most challenging questions. The company generated
revenues of $4.91 billion in fiscal 2018 and employs 15,550 people
worldwide. Information about Agilent is available
at www.agilent.com. To receive the latest Agilent news,
subscribe to our Newsroom. Follow Agilent
on LinkedIn, Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190618005301/en/
Naomi GoumilloutAgilent
Technologies+1.781.266.2819naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024